Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month High – Time to Buy?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $63.97 and last traded at $63.4950, with a volume of 759374 shares changing hands. The stock had previously closed at $60.54.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a research note on Monday, March 9th. Guggenheim reiterated a “buy” rating and issued a $90.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Royal Bank Of Canada increased their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, HC Wainwright boosted their price objective on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $77.20.

Xenon Pharmaceuticals Stock Up 4.3%

The firm has a market cap of $6.10 billion, a PE ratio of -13.43 and a beta of 0.61. The stock has a 50 day moving average price of $55.11 and a two-hundred day moving average price of $50.43.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting the consensus estimate of ($1.17). During the same quarter in the previous year, the business earned ($0.83) earnings per share. As a group, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director directly owned 1,455 shares of the company’s stock, valued at $77,318.70. The trade was a 44.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the transaction, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.07% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in shares of Xenon Pharmaceuticals by 7.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock valued at $14,854,000 after acquiring an additional 32,486 shares during the last quarter. Jump Financial LLC acquired a new position in Xenon Pharmaceuticals during the second quarter valued at $532,000. Sei Investments Co. acquired a new position in Xenon Pharmaceuticals during the second quarter valued at $711,000. The Manufacturers Life Insurance Company purchased a new stake in Xenon Pharmaceuticals in the second quarter valued at $816,000. Finally, Alliancebernstein L.P. boosted its holdings in Xenon Pharmaceuticals by 14.2% in the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after purchasing an additional 189,141 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.